Xeris Retained Earnings from 2010 to 2025

XERS Stock

USD 4.82 0.26 5.70%

Xeris Pharmaceuticals Retained Earnings yearly trend continues to be comparatively stable with very little volatility. Retained Earnings are likely to outpace its year average in 2025. Retained Earnings is the cumulative amount of net income that Xeris Pharmaceuticals retains for reinvestment in its operations, rather than distributing it to shareholders as dividends. View All Fundamentals

Retained Earnings

First Reported

2016-12-31

Previous Quarter

-666.7 M

Current Value

-671.9 M

Quarterly Volatility

214 M

Covid

Check Xeris Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Xeris Pharmaceuticals' main balance sheet or income statement drivers, such as Interest Income of 5.6 M, Depreciation And Amortization of 13.3 M or Interest Expense of 32 M, as well as many indicators such as Price To Sales Ratio of 2.33, Dividend Yield of 0.0 or Days Sales Outstanding of 69.01. Xeris financial statements analysis is a perfect complement when working with Xeris Pharmaceuticals Valuation or Volatility modules.

Check out the analysis of Xeris Pharmaceuticals Correlation against competitors.

For more information on how to buy Xeris Stock please use our How to Invest in Xeris Pharmaceuticals guide.

Latest Xeris Pharmaceuticals' Retained Earnings Growth Pattern

Below is the plot of the Retained Earnings of Xeris Pharmaceuticals over the last few years. It is the cumulative amount of net income that a company retains for reinvestment in its operations, rather than distributing it to shareholders as dividends. Xeris Pharmaceuticals' Retained Earnings historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Xeris Pharmaceuticals' overall financial position and show how it may be relating to other accounts over time.

View

Last Reported (671.86 M)

10 Years Trend

Slightly volatile

Compare to Others All Fundamentals

Retained Earnings

Timeline

Xeris Retained Earnings Regression Statistics

	Arithmetic Mean	(252,486,934)
	Geometric Mean	122,626,931
	Coefficient Of Variation	(104.08)
	Mean Deviation	232,394,668
	Median	(60,585,000)
	Standard Deviation	262,786,439
	Sample Variance	69056.7T
	Range	637.8M
	R-Value	(0.91)
	Mean Square Error	12149.9T
	R-Squared	0.84
	Slope	(50,461,168)
	Total Sum of Squares	1035850.7T

Xeris Retained Earnings History

	2025	-638.3 M
	2024	-671.9 M
	2023	-617 M
	2021	-554.8 M
	2020	-337.4 M
	2019	-246.2 M
	2018	-120.7 M

Other Fundumenentals of Xeris Pharmaceuticals

Retained Earnings Total Equity

Xeris Pharmaceuticals Retained Earnings component correlations

	Total Assets	Total Stockholder Equity	Net Tangible Assets	Current Deferred Revenue	Net Debt	Retained Earnings	Accounts Payable	Net Receivables	Capital Surpluse	Total Liab	Total Current Assets	Short Term Debt	Common Stock	Property Plant Equipment	Net Invested Capital	Net Working Capital	Long Term Debt	Short Term Investments	Long Term Debt Total	Capital Stock	Deferred Long Term Liab	Intangible Assets	Short Long Term Debt
Total Assets		0.5	-0.5	0.86	0.84	-0.96	0.71	0.87	0.9	0.96	0.96	0.47	0.99	0.88	0.96	0.58	0.9	-0.81	0.93	0.98	0.93	0.6	-0.33
Total Stockholder Equity	0.5		0.41	0.4	0.18	-0.36	0.37	0.16	0.54	0.25	0.66	-0.03	0.39	0.37	0.65	0.78	0.22	-0.09	0.43	0.32	0.4	-0.14	0.19
Net Tangible Assets	-0.5	0.41		-0.37	-0.52	0.54	-0.37	-0.66	-0.27	-0.69	-0.27	-0.3	-0.59	-0.42	-0.28	0.21	-0.63	0.76	-0.41	-0.65	-0.46	-0.55	0.38
Current Deferred Revenue	0.86	0.4	-0.37		0.89	-0.94	0.63	0.83	0.96	0.82	0.88	0.52	0.85	0.97	0.89	0.6	0.83	-0.69	0.93	0.85	0.85	0.57	-0.5
Net Debt	0.84	0.18	-0.52	0.89		-0.95	0.52	0.97	0.9	0.85	0.8	0.77	0.85	0.94	0.84	0.47	0.9	-0.84	0.84	0.88	0.8	0.83	-0.72
Retained Earnings	-0.96	-0.36	0.54	-0.94	-0.95		-0.64	-0.95	-0.95	-0.94	-0.92	-0.63	-0.96	-0.96	-0.93	-0.56	-0.93	0.85	-0.93	-0.97	-0.91	-0.71	0.56
Accounts Payable	0.71	0.37	-0.37	0.63	0.52	-0.64		0.53	0.59	0.69	0.63	-0.08	0.7	0.58	0.62	0.18	0.55	-0.49	0.66	0.66	0.62	0.45	0.11
Net Receivables	0.87	0.16	-0.66	0.83	0.97	-0.95	0.53		0.85	0.9	0.79	0.73	0.89	0.91	0.83	0.44	0.95	-0.93	0.81	0.92	0.8	0.83	-0.67
Capital Surpluse	0.9	0.54	-0.27	0.96	0.9	-0.95	0.59	0.85		0.82	0.96	0.6	0.87	0.96	0.96	0.74	0.84	-0.69	0.92	0.87	0.87	0.58	-0.51
Total Liab	0.96	0.25	-0.69	0.82	0.85	-0.94	0.69	0.9	0.82		0.85	0.49	0.99	0.84	0.86	0.37	0.93	-0.86	0.9	0.99	0.91	0.71	-0.37
Total Current Assets	0.96	0.66	-0.27	0.88	0.8	-0.92	0.63	0.79	0.96	0.85		0.47	0.92	0.88	0.99	0.77	0.82	-0.66	0.92	0.89	0.91	0.49	-0.33
Short Term Debt	0.47	-0.03	-0.3	0.52	0.77	-0.63	-0.08	0.73	0.6	0.49	0.47		0.47	0.64	0.52	0.35	0.59	-0.65	0.42	0.52	0.41	0.66	-0.92
Common Stock	0.99	0.39	-0.59	0.85	0.85	-0.96	0.7	0.89	0.87	0.99	0.92	0.47		0.86	0.92	0.49	0.93	-0.83	0.94	0.99	0.94	0.66	-0.35
Property Plant Equipment	0.88	0.37	-0.42	0.97	0.94	-0.96	0.58	0.91	0.96	0.84	0.88	0.64	0.86		0.91	0.62	0.89	-0.79	0.9	0.87	0.82	0.66	-0.58
Net Invested Capital	0.96	0.65	-0.28	0.89	0.84	-0.93	0.62	0.83	0.96	0.86	0.99	0.52	0.92	0.91		0.75	0.86	-0.73	0.91	0.9	0.88	0.55	-0.36
Net Working Capital	0.58	0.78	0.21	0.6	0.47	-0.56	0.18	0.44	0.74	0.37	0.77	0.35	0.49	0.62	0.75		0.49	-0.25	0.6	0.47	0.6	0.11	-0.23
Long Term Debt	0.9	0.22	-0.63	0.83	0.9	-0.93	0.55	0.95	0.84	0.93	0.82	0.59	0.93	0.89	0.86	0.49		-0.87	0.89	0.94	0.88	0.79	-0.46
Short Term Investments	-0.81	-0.09	0.76	-0.69	-0.84	0.85	-0.49	-0.93	-0.69	-0.86	-0.66	-0.65	-0.83	-0.79	-0.73	-0.25	-0.87		-0.66	-0.87	-0.64	-0.73	0.59
Long Term Debt Total	0.93	0.43	-0.41	0.93	0.84	-0.93	0.66	0.81	0.92	0.9	0.92	0.42	0.94	0.9	0.91	0.6	0.89	-0.66		0.92	0.97	0.59	-0.31
Capital Stock	0.98	0.32	-0.65	0.85	0.88	-0.97	0.66	0.92	0.87	0.99	0.89	0.52	0.99	0.87	0.9	0.47	0.94	-0.87	0.92		0.93	0.69	-0.42
Deferred Long Term Liab	0.93	0.4	-0.46	0.85	0.8	-0.91	0.62	0.8	0.87	0.91	0.91	0.41	0.94	0.82	0.88	0.6	0.88	-0.64	0.97	0.93		0.59	-0.3
Intangible Assets	0.6	-0.14	-0.55	0.57	0.83	-0.71	0.45	0.83	0.58	0.71	0.49	0.66	0.66	0.66	0.55	0.11	0.79	-0.73	0.59	0.69	0.59		-0.54
Short Long Term Debt	-0.33	0.19	0.38	-0.5	-0.72	0.56	0.11	-0.67	-0.51	-0.37	-0.33	-0.92	-0.35	-0.58	-0.36	-0.23	-0.46	0.59	-0.31	-0.42	-0.3	-0.54

Click cells to compare fundamentals

About Xeris Pharmaceuticals Financial Statements

Xeris Pharmaceuticals shareholders use historical fundamental indicators, such as Retained Earnings, to determine how well the company is positioned to perform in the future. Although Xeris Pharmaceuticals investors may analyze each financial statement separately, they are all interrelated. The changes in Xeris Pharmaceuticals' assets and liabilities, for example, are also reflected in the revenues and expenses on on Xeris Pharmaceuticals' income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.

	Last Reported	Projected for Next Year
Retained Earnings	-671.9 M	-638.3 M
Retained Earnings Total Equity	-303.7 M	-318.8 M

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.

Explore Investing Ideas

Additional Tools for Xeris Stock Analysis

When running Xeris Pharmaceuticals' price analysis, check to measure Xeris Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Xeris Pharmaceuticals is operating at the current time. Most of Xeris Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Xeris Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Xeris Pharmaceuticals' price. Additionally, you may evaluate how the addition of Xeris Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC